SALT
LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion
(NASDAQ: RXRX), the clinical-stage biotechnology company
industrializing drug discovery by decoding biology, today announced
that it recently received a Prime Rating for ESG performance from
the industry-renowned Institutional Shareholder Services (ISS),
which is the first time Recursion has been ranked by ISS. The ISS
ESG Corporate Rating provides an assessment of a company's
environmental, social, and governance activity. A Prime Rating is
awarded to companies with ESG performance above a sector-specific
threshold and is defined by ISS as "absolute best in class".
"We are proud to receive a Prime Rating by ISS for ESG," said
Chris Gibson, Ph.D., Co-Founder
& CEO of Recursion. "As a company looking to revolutionize the
drug discovery industry, it is critical that we focus on building a
sustainable culture that not only fosters interdisciplinary work
across healthcare and technology, but also achieves the highest
standards in mitigating our environmental impact and creating an
inclusive, diverse, and equitable workplace in order to drive
long-term success in the years to come."
Additionally, on September 29,
2022, Recursion plans to participate in the Goldman Sachs
Global Sustainability Forum to share more about its ESG
strategy and connect with the ESG investor community.
Recursion's Prime Rating from ISS follows the release of
Recursion's first ESG report earlier this year, which outlines the
Company's approach, practices and goals in several important areas.
As part of the report, Recursion announced long-term commitments
focused on net-zero greenhouse gas emissions, workforce diversity,
and philanthropy.
The full 2022 Recursion ESG Report can be found here.
More information on ISS ESG Corporate Ratings can be found
here.
About Recursion
Recursion is the clinical-stage
biotechnology company industrializing drug discovery by decoding
biology. Enabling its mission is the Recursion OS, a platform built
across diverse technologies that continuously expands one of the
world's largest proprietary biological and chemical datasets.
Recursion leverages sophisticated machine-learning algorithms to
distill from its dataset a collection of trillions of searchable
relationships across biology and chemistry unconstrained by human
bias. By commanding massive experimental scale — up to millions of
wet lab experiments weekly — and massive computational scale —
owning and operating one of the most powerful supercomputers in the
world, Recursion is uniting technology, biology and chemistry to
advance the future of medicine.
Recursion is headquartered in Salt
Lake City, where it is a founding member of BioHive, the
Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the San
Francisco Bay Area. Learn more at www.Recursion.com, or
connect on Twitter and LinkedIn.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Forward-Looking Statements
This document contains
information that includes or is based upon "forward-looking
statements" within the meaning of the Securities Litigation Reform
Act of 1995, including, without limitation, those regarding early
and late stage discovery, preclinical, and clinical programs;
licenses and collaborations; prospective products and their
potential future indications and market opportunities; Recursion OS
and other technologies; business and financial plans and
performance; and all other statements that are not historical
facts. Forward-looking statements may or may not include
identifying words such as "plan," "will," "expect," "anticipate,"
"intend," "believe," "potential," "continue," and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
insufficient efficacy, safety considerations, or other factors; our
ability to leverage and enhance our drug discovery platform; our
ability to obtain financing for development activities and other
corporate purposes; the success of our collaboration activities;
our ability to obtain regulatory approval of, and ultimately
commercialize, drug candidates; the impact of the COVID-19 pandemic
and force majeure events; our ability to obtain, maintain, and
enforce intellectual property protections; cyberattacks or other
disruptions to our technology systems; our ability to attract,
motivate, and retain key employees and manage our growth; inflation
and other macroeconomic issues; and other risks and uncertainties
such as those described under the heading "Risk Factors" in our
filings with the U.S. Securities and Exchange Commission, including
our most recent Quarterly Report on Form 10-Q and our Annual Report
on Form 10-K. All forward-looking statements are based on
management's current estimates, projections, and assumptions, and
Recursion undertakes no obligation to correct or update any such
statements, whether as a result of new information, future
developments, or otherwise, except to the extent required by
applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/recursion-receives-iss-esg-prime-rating-and-plans-to-participate-in-the-goldman-sachs-global-sustainability-forum-301608050.html
SOURCE Recursion